Payment overview · 2025
General Payments
$1,431.48
78 reported records · 15 companies
Healthcare provider profile · identity verified
Michele Lee Keesling, NP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Adult Health · GALAX, VA · NPI 1659824332
Verified facts
What the public records show
CMS Open Payments records show Michele Lee Keesling, NP received $1,431.48 in general payments during 2025 across 78 reported records.
ABBVIE INC. accounted for 28.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Linzess, Mounjaro, Nurtec Odt, Ozempic, Qulipta, Rexulti, Ubrelvy, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Ubrelvy by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $407.58 | 28.5% | 26 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $239.74 | 16.8% | 11 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $168.50 | 11.8% | 9 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $118.71 | 8.3% | 6 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $101.89 | 7.1% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $89.33 | 6.2% | 5 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $61.04 | 4.3% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $59.17 | 4.1% | 3 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $41.64 | 2.9% | 2 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $36.00 | 2.5% | 2 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $31.93 | 2.2% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $23.48 | 1.6% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $21.83 | 1.5% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $16.86 | 1.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $13.78 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,430.28 | 77 |
| Education | $1.20 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $279.86 | 18 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $239.74 | 11 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $168.50 | 9 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $142.19 | 7 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $108.62 | 7 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $108.62 | 7 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $101.89 | 6 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $80.78 | 5 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $61.04 | 3 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $41.64 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $41.25 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $39.66 | 2 | 2025 |
Source payment records
|
|||||
| INVEGA SUSTENNA Normalized: invega sustenna |
Drug | Janssen Pharmaceuticals, Inc | $31.93 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $21.83 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $19.51 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $19.10 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $19.10 | 1 | 2025 |
Source payment records
|
|||||
| VIVITROL Normalized: vivitrol |
Drug | Alkermes, Inc. | $18.18 | 1 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $17.82 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $17.76 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $17.76 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $16.86 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $13.78 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $13.78 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| LINZESS linzess |
2025 | Linzess | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 46 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 61 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
61 | 14 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
101 | 24 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 241 | 61 |
| Gabapentin | Gabapentin | 182 | 36 |
| Prednisone | Prednisone | 174 | 78 |
| Furosemide | Furosemide | 170 | 55 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 166 | 45 |
| Levothyroxine Sodium | Levothyroxine Sodium | 161 | 42 |
| Omeprazole | Omeprazole | 157 | 51 |
| Azithromycin | Azithromycin | 145 | 104 |
| Lisinopril | Lisinopril | 131 | 42 |
| Amlodipine Besylate | Amlodipine Besylate | 126 | 39 |
| Pantoprazole Sodium | Pantoprazole Sodium | 122 | 34 |
| Potassium Chloride | Potassium Chloride | 120 | 42 |
| Eliquis | Apixaban | 101 | 24 |
| Montelukast Sodium | Montelukast Sodium | 100 | 27 |
| Trazodone Hcl | Trazodone Hcl | 99 | 30 |
| Zolpidem Tartrate | Zolpidem Tartrate | 90 | 18 |
| Famotidine | Famotidine | 87 | 31 |
| Escitalopram Oxalate | Escitalopram Oxalate | 80 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 80 | 24 |
| Losartan Potassium | Losartan Potassium | 79 | 23 |
| Sertraline Hcl | Sertraline Hcl | 78 | 21 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 76 | 50 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 76 | 25 |
| Metoprolol Succinate | Metoprolol Succinate | 76 | 24 |
| Diclofenac Sodium | Diclofenac Sodium | 73 | 25 |
| Amoxicillin | Amoxicillin | 70 | 49 |
| Quetiapine Fumarate | Quetiapine Fumarate | 68 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 66 | 18 |
| Buspirone Hcl | Buspirone Hcl | 65 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 64 | 21 |
| Ibuprofen | Ibuprofen | 63 | 21 |
| Meloxicam | Meloxicam | 63 | 14 |
| Nystatin | Nystatin | 61 | 35 |
| Ozempic | Semaglutide | 61 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 60 | 43 |
| Celecoxib | Celecoxib | 59 | 17 |
| Clonazepam | Clonazepam | 59 | 15 |
| Levofloxacin | Levofloxacin | 58 | 35 |
| Fluconazole | Fluconazole | 57 | 27 |
| Ondansetron Odt | Ondansetron | 57 | 21 |
| Topiramate | Topiramate | 57 | 11 |
| Alprazolam | Alprazolam | 56 | 14 |
| Lorazepam | Lorazepam | 56 | 26 |
| Mirtazapine | Mirtazapine | 56 | 17 |
| Tamsulosin Hcl | Tamsulosin Hcl | 56 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 54 | 21 |
| Metformin Hcl | Metformin Hcl | 54 | 15 |
| Pregabalin | Pregabalin | 54 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 52 | 15 |
| Bumetanide | Bumetanide | 51 | 12 |
| Metformin Hcl Er | Metformin Hcl | 51 | 11 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 48 | 15 |
| Mounjaro | Tirzepatide | 46 | suppressed |
| Methocarbamol | Methocarbamol | 45 | 15 |
| Bupropion Xl | Bupropion Hcl | 44 | 12 |
| Cephalexin | Cephalexin | 44 | 27 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 44 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 44 | 26 |
| Amitriptyline Hcl | Amitriptyline Hcl | 43 | suppressed |
| Memantine Hcl | Memantine Hcl | 39 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 37 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 36 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 36 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 36 | 18 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 34 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 33 | 21 |
| Rizatriptan | Rizatriptan Benzoate | 33 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 33 | 19 |
| Farxiga | Dapagliflozin Propanediol | 31 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 30 | suppressed |
| Atenolol | Atenolol | 29 | suppressed |
| Spironolactone | Spironolactone | 29 | suppressed |
| Allopurinol | Allopurinol | 28 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 28 | suppressed |
| Glipizide | Glipizide | 27 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 27 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 25 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 25 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 25 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 24 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 24 | suppressed |
| Vraylar | Cariprazine Hcl | 24 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 23 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 23 | suppressed |
| Dexamethasone | Dexamethasone | 22 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 22 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 22 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 22 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 21 | suppressed |
| Lovastatin | Lovastatin | 21 | suppressed |
| Methylprednisolone | Methylprednisolone | 21 | 19 |
| Ofloxacin | Ofloxacin | 21 | 17 |
| Humalog Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | suppressed |
| Belsomra | Suvorexant | 19 | suppressed |
| Simvastatin | Simvastatin | 19 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 18 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 18 | suppressed |
| Sucralfate | Sucralfate | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 17 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 17 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | 13 |
| Ibu | Ibuprofen | 15 | suppressed |
| Rexulti | Brexpiprazole | 15 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Methotrexate | Methotrexate Sodium | 14 | suppressed |
| Olanzapine | Olanzapine | 14 | suppressed |
| Synthroid | Levothyroxine Sodium | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Ubrelvy | Ubrogepant | 14 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 14 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Carvedilol | Carvedilol | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 13 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 13 | suppressed |
| Tri-Sprintec | Norgestimate-Ethinyl Estradiol | 13 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Finasteride | Finasteride | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Latanoprost | Latanoprost | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Oxycontin | Oxycodone Hcl | 12 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Motegrity | Prucalopride Succinate | 11 | suppressed |
| Qulipta | Atogepant | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,431.48 · 78 records | ABBVIE INC. | AIRSUPRA, Auvelity, CAPLYTA, CREON, Dexcom G6 Transmitter, FANAPT, FREESTYLE LIBRE 3, GVOKE HYPOPEN, HETLIOZ, INVEGA SUSTENNA, LINZESS, LYBALVI, MOUNJARO, NURTEC ODT, Ozempic, QULIPTA, REXULTI, Rybelsus, UBRELVY, VIVITROL, VRAYLAR, Wegovy, ZAVZPRET, ZEPBOUND | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Linzess play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error